Value-Based Pricing and Market Access Strategies for Innovative Pharmaceuticals: A Systematic Review

Background: Value-based pricing (VBP) has become the dominant normative framework for pricing innovative medicines, yet its operational translation into market access outcomes remains contested. Between 2014 and 2024 the pricing environment shifted from a system of largely national, list-price-anchored negotiation toward one characterised by mandatory public negotiation in the United States, harmonised clinical assessment in the European Union, and a rapid proliferation of outcomes-linked contracting for one-time therapies. These developments have outpaced the conceptual literature on which VBP was founded.

Objectives: This review had four objectives: (1) to characterise how value-based pricing is defined and operationalised across health systems; (2) to map the market access strategies manufacturers deploy in response to value-based reimbursement environments; (3) to synthesise the empirical evidence on whether these strategies improve access, affordability, and allocative efficiency; and (4) to identify the structural barriers that separate VBP as a policy ideal from VBP as implemented practice.

Methods: A systematic search of MEDLINE, Embase, EconLit, Scopus, Web of Science, the Cochrane Library, and the NHS Economic Evaluation Database, supplemented by backward and forward citation chaining, was combined with structured grey-literature searching of health technology assessment (HTA) agency repositories, the European Commission HTA portal, the Centers for Medicare and Medicaid Services (CMS) document library, the OECD iLibrary, WHO publications, and the websites of ISPOR, the Office of Health Economics, and EFPIA. Eligible records were peer-reviewed empirical studies, policy analyses, systematic and scoping reviews, and authoritative agency documents addressing value-based pricing, HTA-linked reimbursement, managed entry agreements, or market access strategy for innovative pharmaceuticals. Screening was conducted in duplicate against pre-specified criteria. Quality was appraised using the Mixed Methods Appraisal Tool, the Drummond checklist for economic evaluations, and a bespoke credibility rubric for policy and grey-literature sources. Findings were synthesised narratively using thematic framework analysis, with a subgroup analysis by jurisdiction, therapeutic modality, and agreement type.

Results: The literature converges on a common conceptual definition of VBP, namely that price should reflect the incremental value a technology delivers relative to relevant comparators, but diverges sharply on what counts as value, whose perspective defines it, and how residual uncertainty should be priced. Twelve themes were identified: conceptual fragmentation of value; the contested empirical basis of the cost-effectiveness threshold; institutional heterogeneity in HTA architecture; uncertainty and the reliance on surrogate endpoints at the point of pricing; the shift from financial to outcomes-based contracting; the data infrastructure and real-world evidence constraint; launch sequencing, international price interdependence and price confidentiality; the distinct economics of advanced therapy medicinal products; the special-status debate surrounding orphan medicines; delinked payment for antimicrobials; equity, affordability and distributional analysis including low- and middle-income and emerging markets; and the reshaping of evidentiary requirements by statutory price negotiation. The most consistent empirical finding across the corpus is an implementation gap. Outcomes-based agreements are widely endorsed in principle, comparatively rare in execution, and frequently abandoned when parties discover that agreed outcome metrics cannot be tracked in routine care. Financial agreements, principally confidential discounts, remain the workhorse instrument in almost every jurisdiction studied. Evidence that VBP mechanisms measurably improve population health outcomes, as distinct from managing payer budget risk, is thin and of low certainty.

Conclusions: Value-based pricing is best understood as a family of negotiation heuristics rather than a single pricing algorithm. Its effectiveness is bounded less by economic theory than by three practical constraints: the quality of real-world data infrastructure, the administrative cost of contract execution, and the political economy of price confidentiality. The convergence of statutory price negotiation in the United States with the forthcoming application of the EU HTA Regulation from January 2025 is shifting the locus of value determination from national deliberation toward supranational assessment and formula-driven price setting. Manufacturers responding to this environment require evidence strategies designed simultaneously for multi-jurisdictional clinical assessment, statutory negotiation, and outcomes-linked contracting. Research priorities include prospective evaluation of executed outcomes-based agreements, standardised reporting of net prices, and methods for pricing under indication multiplicity.